TMG-39

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: TMG-39
• 英文别名: 7-Chloro-1-methyl-3-[(4-phenylphenyl)methyl]-3,4-dihydro-1,4-benzodiazepine-2,5-dione
• 化学式: C₂₃H₁₉ClN₂O₂
• 分子量: 390.869
• InChiKey: DARZPDALSPKJHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-苯基-DL-苯丙氨酸 、 5-氯-N-甲基靛红酸酐 在 溶剂黄146 作用下， 反应 7.0h， 生成 TMG-39
  参考文献：
  名称：

  鉴定具有细胞毒性的T细胞选择性1,4-苯并二氮杂2,5-二酮。

  摘要：

  已经合成了1,4-苯并二氮杂-2,5-二酮（BZDs）家族，并针对转化的B细胞和T细胞进行了淋巴毒性检测。C3位置上的一个较大的芳族基团对于细胞毒性至关重要。当C3部分包含一个富含电子的杂环时，所得BZD具有亚微摩尔浓度，并且对T细胞具有选择性。细胞死亡与细胞凋亡一致，而不是由于线粒体F（o）F1-ATPase的抑制而引起的，线粒体F（o）F1-ATPase是最近报道的具有细胞毒性的1,4-苯并二氮杂the的分子靶标。集体地，这些研究开始表征一些新型T细胞选择性淋巴毒性药物家族的活性所需的结构要素。

  DOI：

  10.1016/j.bmcl.2006.01.113

文献信息

• 1,4-BENZODIAZEPINE-2,5-DIONES AND RELATED COMPOUNDS WITH THERAPEUTIC PROPERTIES
  申请人：Glick Gary D.

  公开号：US20120270862A1

  公开（公告）日：2012-10-25

  The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzo-diazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity.

  本发明提供了新型化合物，其特征是Rho激酶（ROCK）抑制剂，以及它们的发现方法和它们的治疗、研究和诊断用途。特别是，本发明提供了具有ROCK抑制活性的1,4-苯并二氮平-2,5-二酮化合物和相关化合物，以及使用这些化合物作为治疗剂治疗与ROCK活性相关的多种疾病的方法。
• 1,4-Benzodiazepone-2,5-Diones And Related Compounds With Therapeutic Properties
  申请人：The Regents of the University of Michigan

  公开号：US20160095866A1

  公开（公告）日：2016-04-07

  The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity.

  本发明提供了新型化学化合物，其特征为Rho激酶（ROCK）抑制剂，以及发现这些化合物的方法和它们的治疗、研究和诊断用途。特别地，本发明提供了具有ROCK抑制活性的1,4-苯二氮平-2,5-二酮化合物和相关化合物，并提供了使用这些化合物作为治疗剂治疗与ROCK活性相关的多种疾病的方法。
• UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS
  申请人：Glick Gary D.

  公开号：US20120077805A1

  公开（公告）日：2012-03-29

  The present invention relates to systems and methods for generating new forms of benzodiazepine and benzodiazepine related compounds as well as new compounds and formulations generated by such methods. In particular, the present invention provides high throughput systems and methods for generating and identifying new crystalline benzodiazepine and benzodiazepine related polymorphs and new unsolvated, solvated, and other forms of the compounds that find use as improved drugs and drug formations.
• NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES
  申请人：Glick Gary D.

  公开号：US20120088757A1

  公开（公告）日：2012-04-12

  The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4-benzodiazepine-2,5-dione compounds, and methods of using novel 1,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.
• US8088759B2
  申请人：——

  公开号：US8088759B2

  公开（公告）日：2012-01-03